Brief: Acurx Pharmaceuticals Announces $2.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
06/01/2025 23:01
Jan 6 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX PHARMACEUTICALS, INC. ANNOUNCES $2.5 MILLION
REGISTERED
DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Source text: ID:nPn5VTKvsa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program